286
Views
7
CrossRef citations to date
0
Altmetric
Original Articles: Gynaecology

Confounding factors of transvaginal ultrasound accuracy in endometrial cancer

ORCID Icon, , , , , , , , , ORCID Icon & show all
 

Abstract

Endometrial cancer is the most frequently diagnosed gynecological tumour. Transvaginal ultrasound has a leading role in the preoperative evaluation of endometrial cancer patients. The study aimed to identify factors that can worsen the diagnostic accuracy of transvaginal ultrasound in endometrial cancer patients. We retrospectively analysed 290 patients with histological diagnosis of endometrial adenocarcinoma. Two-dimensional (2D) gray-scale ultrasound and power Doppler imaging were performed. Age, menopause status, obesity, parity, Figo stage and benign uterine disorders were evaluated as possible factors worsening the diagnostic accuracy of the ultrasonography. FIGO stage IB was the main significant confounding factor in the univariate analysis (p = .004). Furthermore, 2D transvaginal ultrasound showed worse diagnostic accuracy in endometrial cancer patients with concomitant benign uterine pathologies.

    Impact statement

  • What is already known on this subject? Many studies have analysed the reliability and diagnostic accuracy of transvaginal ultrasound in predicting myometrial invasion, but few studies have underlined the importance of confounding factors. Shin et al. (Citation2011) showed that diffuse fibromatosis is a quality ultrasound confounding factor. Furthermore, Fischerova et al. (Citation2014) showed that body mass index (BMI) did not influence the diagnostic accuracy of ultrasound assessment.

  • What do the results of this study add? FIGO stage IB is the main factor worsening the diagnostic accuracy of transvaginal ultrasound in endometrial cancer patients (p = .004). Among the 82 patients with histologically proven FIGO stage IB, 27 (32.9%) had a wrong ultrasound prediction of myometrial infiltration. Twenty-one (36.2%) patients in whom there was no agreement between ultrasound prediction of myometrial infiltration and pathological analysis had fibromatosis and/or adenomyosis (p = 0.04).

  • What are the implications of these findings for clinical practice and/or further research? Two-dimensional ultrasound represents a useful tool in the correct pre-operative setting of patients with endometrial cancer. In FIGO stages IB endometrial cancer patients and in conjunction with benign uterine pathologies, 2D transvaginal ultrasound has less diagnostic accuracy. In these cases, MRI still plays a leading role.

Synopsis

In deeply infiltrating endometrial cancer, 2-D transvaginal ultrasound has less diagnostic accuracy and MRI still plays a leading role.

Author contributions

Capozzi VA: Project development, Data Collection, Manuscript writing

Merisio C: Protocol/project development

Rolla M: Project development, Data Collection

Pugliese M: Data Collection

Morganelli G: Manuscript writing

Cianciolo A: Data Collection

Gambino G: Data Collection

Armano G: Project development

Sozzi G: Project development

Riccò M: Data analysis

Berretta R: Project development, Manuscript writing, and editing

Disclosure statement

All patients provided their informed consent. No funding was received from any of the authors. None of the authors has a conflict of interest to declare. The study was approved by the local ethics committee with the following protocol number ETV2D2018.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.